Istanbul, Turkey, 15th September 2009 – Further evidence of the superior antidepressant efficacy of Valdoxan®/Thymanax® (agomelatine) over conventional selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitor (SNRI) antidepressants was presented today at the Servier satellite symposium on the occasion of the 22nd European College of Neuropsychopharmacology (ECNP) Congress, with educational financial support provided [...]

Valdoxan 25 mg film-coated tablets
Agomelatine
Read all of this leaflet carefully before you start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, [...]

1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
4.2 Posology and method of administration
4.3 Contraindications
4.4 Special warnings and precautions for use
[...]

Valdoxan provides MDD patients with a significant symptomatic relief, as demonstrated by well-documented improvements in depressed mood, anxiety symptoms, and also sleep-wake disturbances (daytime impairment and sleep disturbances).
Efficacy of Valdoxan on depressed mood
Valdoxan has been demonstrated to be significantly effective in relieving depressed mood of patients with MDD, the most characteristic symptom of depression.
In a [...]